rhGH therapy does not unmask central hypoadrenalism in children with idiopathic GHD
This article has no abstract so we have provided the first paragraph of the full text.
Adults with organic growth-hormone deficiency (GHD) treated with recombinant human growth hormone (rhGH) require reassessment of their hypothalamic–pituitary–adrenal (HPA) axis function because this therapy could unmask central hypoadrenalism. Whether children with idiopathic GHD require HPA reassessment during rhGH therapy is, however, unknown. Giavoli et al. evaluated HPA function in children with idiopathic GHD before and during rhGH therapy.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
